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Abstract 
Early therapies for acute traumatic spinal 
cord injury has some key points: 
1. Immediately or soon after the injury is 
recommended a hemodynamic support to 
maintain mean arterial pressure at 85 – 90 
mmHg and monitoring in an intensive care 
unit for the first week after spinal cord 
injury. 
2. Immediate surgery for spinal cord 
decompression is of high importance for 
the prognosis and evolution of spinal cord 
injury.    
3. The recommendation is to treat all 
patients with spinal cord injury  according 
to the local protocol, methylprednisolone is 
not standard of care anymore, it is a 
treatment option that should only be 
undertaken with knowledge of the potential 
complications. 
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In April in Canadian Medical 
Association Journal was published an 
excellent review of the acute traumatic 
spinal cord injury problem:  "Emerging 
therapies for acute traumatic spinal cord 
injury" written by Jefferson R. Wilson, 
Nicole Forgione and Michael G. Fehlings 
(CMAJ, vol. 185 no. 6, pp.485 - 492, 2013). 
In the beginning the article show  the 
incidence and prevalence of traumatic 
spinal cord injury in Canada; for us this is a 
serious problem!  We have not a situation of 
these cases in Romania, therefore  we have 
not a national perspective on the  incidence 
and prevalence of spinal cord injury in our 
country.  Neurosurgical  and 
neurorehabilitation departments  must keep 
track of cases of spinal trauma and each 
statistic should be centralized. 
Following the protocols developed for 
the spinal cord injury patients the care on 
the first 72 hours of injury are the most 
important and all must prevent secondary 
complications. 
After a good triage protocols and trauma 
systems of care, including prehospital 
triage, spinal stabilization during emergency 
transport and early immobilization of all 
patients with a potential spinal injury, 
patient arrives at the spinal cord injury 
center.  Initial prehospital management of 
traumatic acute spinal cord injury is crucial 
for the morbidity and mortality following 
acute spinal cord injury. 
The radiographic evaluation of patients 
following spinal cord injury consists of the 
images of the entire spine and to perform 
MRI of the known or suspected ares of 
spinal cord injury. 
In the spinal cord injury center the 
patient receives “aggressive medical and 
surgical methods to maintain cord 
perfusion, avoiding complications, 
decompressing the spinal cord and 
restoring stability.” (citare Emerging).  The 
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authors recommend to maintain mean 
arterial pressure at  85 – 90 mmHg and 
monitoring in an intensive care unit for the 
first week after spinal cord injury. These 
recommendations are consistent with 
recommendations of  the American 
Association of Neurological Surgeons: that 
patients’ mean arterial pressure must be 
maintained at 85–90 mmHg for the first 7 
days after injury, published since 2002, in 
article: “Blood pressure management after 
acute spinal cord injury” Neurosurgery. 
Also “when volume replacement is 
inadequate to achieve this goal, intravenous 
vasopressor medications may be 
introduced. Patients, particularly those with 
severe cervical injuries, should receive 
treatment in an intensive care unit (ICU) 
with continuous cardiac, hemodynamic and 
respiratory monitoring for the first 7–14 
days after injury. In observational studies, 
the standardized admission of patients with 
spinal injuries to an ICU has been 
associated with reduced mortality and 
morbidity, in addition to improved 
neurologic recovery.” (citare Emerging ). 
The surgical treatment (ideally - within 
eight hours of the injury occuring) must 
remove the tissues causing spinal cord  
compression, must correct the 
misalignment and must stabilize the spine.  
Immediate surgery for spinal cord 
decompression is of high importance for 
the prognosis and evolution of spinal cord 
injury.   STASCIS, the Surgical Timing in 
Acute Spinal Cord Injury Study,   was a 
prospective study that compares patients  
who underwent either early (< 24 h after 
injury) or late ( ≥ 24 h after injury) surgical 
decompression and the results were early 
surgery were associated with better 
neurologic recovery at 6 months. 
 
 
Figure 1 
C5 cervical spinal fracture with traumatic acute 
spinal cord hemorrhage, tetraplegia 
 
Figure 2 
T 10  fracture with traumatic acute spinal cord 
injury, paraplegia 
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Thefore the conclusion is that: 
“decompressive surgery within 24 hours 
after injury has been shown to be safe and 
feasible; in prospective nonrandomized 
trials, it has been associated with improved 
rates of neurologic recovery.” 
There are still other drugs which can be 
used and the recommendation is to treat all 
patients with spinal cord injury  according 
to the local protocol. 
 If steroids are recommended, they 
should be initiated within 8 hours of injury 
with the following steroid protocol: 
methylprednisolone 30 mg/kg bolus over 15 
minutes and an infusion of 
methylprednisolone at 5.4 mg/kg/h for 23 
hours beginning 45 minutes after the bolus. 
Methylprednisolone is not standard of care 
anymore, “optional at best, although could 
still be considered in view of the lack of 
other treatment options”.  
Other drugs with therapeutic potential 
in acute spinal cord injury are:  
- Naloxone, an opioid antagonist that 
blocks the neurotoxic effects of the 
endogenous opioid. 
- Nimodipine, as a  L-type calcium-
channel blocker and it  prevents activation 
of calciumdependent 
apoptotic enzymes and blocks 
presynaptic release of glutamate 
- Minocycline promotes functional 
recovery, enhances axonal survival, and 
reduces injury-site lesion size.  
- GM-1 ganglioside (Sygen) decreases 
injury-induced, over-release of damage-
perpetuating excitatory substances.  
- Riluzole, a sodium-channel blocker 
used for the treatment of amyotrophic 
lateral sclerosis (ALS), in which it reduces 
motor neuron degeneration and in  
preclinical models of spinal cord injury it 
decreases secondary injury by blocking 
pathological activation of sodium channels 
and reducing the release of neuronal 
glutamate. 
- Erytropoietin has neuroprotective 
effects and contributes to neurons 
regeneration  
- Neotrofin stimulat es growth-factor 
production, enhances proliferation of CNS 
stem cells, and protects neurons from the 
release of excitatory substances.  
The implant  in the site of spinal cord 
injury or the transplantation of stem cells 
and autologous non–stem cells has been 
studied in preclinical injury models. 
The  cellular subtypes used for this 
purpose include: 
-  Bone marrow–derived stem cells,  
-  Olfactory ensheathing cells, 
-  Schwann cells,  
-  Activated autologous macrophages,  
-  Tissue-derived adult neural stem cells. 
The results are promising, but further 
studies are needed on larger groups of 
patients with spinal cord injury. 
Conclusions 
The patient with spinal cord injury must 
reach in the spine surgery service as early as 
possible to evaluate the need for immediate 
decompression and stabilization surgery. 
Methylprednisolone is not standard of care 
anymore, optional at best, although could 
still be considered in view of the lack of 
other treatment options.  The patient with 
spinal cord injury must admitt to an 
intensive care unit with continuous cardiac, 
hemodynamic and respiratory monitoring 
for the first 1–2 weeks. 
 
This article about early treatments in 
acute traumatic spinal cord injury is part of 
the grant: “Immediate neuroprotective 
therapy in acute traumatic spinal cord 
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injury”, that won the 2011 national 
competition of National Research Council 
(CNCS), Ideas, grant number: PN-II-ID- 
PCE-2011-3-0569, funded by CNCS –
UEFISCDI Romania 
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